Details for Patent: 8,097,651

Which drugs does patent 8,097,651 protect, and when does it expire?

Patent 8,097,651 protects CAMBIA and is included in one NDA.

This patent has thirty-four patent family members in twenty-three countries.

Summary for Patent: 8,097,651

Scope and claims summary:

Title:	Diclofenac formulations and methods of use
Abstract:	Methods and formulations are provided for treating migraine and other acute pain episodes using diclofenac, and formulations of diclofenac that provide both rapid and sustained relief from acute pain. Methods and formulations are also provided for treating symptoms that often accompany migraine and acute pain such as photophobia, phonophobia, nausea and vomiting.
Inventor(s):	Reiner; Giorgio (Como, IT), Reiner; Alberto (Como, IT), Meyer; Andreas (Neuenberg, DE)
Assignee:	APR Applied Pharma Research s.a. (CH)
Application Number:	12/683,517
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,097,651
Patent Claim Types: see list of patent claims	Use; Composition; Formulation;

Drugs Protected by US Patent 8,097,651

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Assertio	CAMBIA	diclofenac potassium	FOR SOLUTION;ORAL	022165-001	Jun 17, 2009	AB	RX	Yes	Yes	8,097,651		Y	Y		ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS

International Family Members for US Patent 8,097,651

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	057378
Australia	2006257072
Brazil	PI0612245
Canada	2632375
Canada	2932603